Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Blueprint Medicines Corporation - Common Stock (NQ: BPMC ) 91.62 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Blueprint Medicines Corporation - Common Stock < Previous 1 2 3 4 5 6 Next > Is NASDAQ:BPMC a Fit for high Growth Investing Strategies? December 03, 2024 Why the high growth investor may take a look at BLUEPRINT MEDICINES CORP (NASDAQ:BPMC). Via Chartmill Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst November 14, 2024 JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities. Via Benzinga Key Takeaways From Blueprint Medicines Analyst Ratings November 14, 2024 Via Benzinga Analyst Ratings For Blueprint Medicines October 24, 2024 Via Benzinga 9 Health Care Stocks Whale Activity In Today's Session August 13, 2024 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session August 08, 2024 Via Benzinga 15 Analysts Have This To Say About Blueprint Medicines July 29, 2024 Via Benzinga Expert Ratings For Blueprint Medicines June 28, 2024 Via Benzinga Assessing Blueprint Medicines: Insights From 16 Financial Analysts June 07, 2024 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session July 30, 2024 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session May 17, 2024 Via Benzinga Unveiling 18 Analyst Insights On Blueprint Medicines May 14, 2024 Via Benzinga BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday May 02, 2024 Via Benzinga The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts April 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session May 01, 2024 Via Benzinga Decoding 6 Analyst Evaluations For Blueprint Medicines April 10, 2024 Via Benzinga (BPMC) - Analyzing Blueprint Medicines's Short Interest February 20, 2024 Via Benzinga Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday February 15, 2024 U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Earnings Scheduled For February 15, 2024 February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. Via Benzinga Blueprint Medicines's Earnings Outlook February 14, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines February 13, 2024 Via Benzinga Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights January 09, 2024 Via Benzinga Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing. February 15, 2024 The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report. Via Investor's Business Daily Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know December 22, 2023 Via Benzinga Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success? December 13, 2023 Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Via Talk Markets Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session December 11, 2023 Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... Via Benzinga The Latest Analyst Ratings for Blueprint Medicines December 11, 2023 Via Benzinga Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know October 27, 2023 Via Benzinga Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know October 27, 2023 Via Benzinga < Previous 1 2 3 4 5 6 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
